美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Corgi All World 2x Daily ETF

24.39

+0.57012.39%

盤後：23.82-0.5701-2.34%16:10 EDT

成交量：16

成交額：406

市值：36.59萬

市盈率：- -

高：24.39

開：23.82

低：24.39

收：23.82

52周最高：25.58

52周最低：20.48

股本：1.50萬

流通股本：1.50萬

量比：0.16

換手率：0.11%

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

港股CXO近日股價集體走高，盈警之後的泰德醫藥(03880)將逆市下跌還是超跌反彈？

【券商聚焦】中信建投：CXO 行業復甦明確，海內外醫藥投融資同步回暖

中信建投：CXO板塊Beta穩中向好，AI製藥大有可為

CXO巨頭爆量上漲！開盤45分鐘成交120億元，超上日全天！規模最大醫療ETF（512170）創本輪反彈新高

反轉信號已現，藥明只是導火索

創新藥產業鏈全線走強！CXO巨頭半年淨利首超百億元，績後飆漲逾10%！創新藥龍頭回暖，520880放量上探2.58%

港股異動 | CRO概念股漲幅居前近期多家海外MNC與CXO披露中報盈喜並上調全年指引

業績炸裂！全年收入劍指605億，藥明康德AH股價狂飆！高「CXO含量」港股通醫療ETF華寶（159137）暴升逾5%！

再次突破半年線！全市場規模最大醫療ETF（512170）摸高1.54%，AI醫療、CXO攜手拉漲！港股通醫療同步走強

【券商聚焦】中信建投：CXO個股訂單加速兑現，行業內需企穩回升

醫藥外包概念全線揚升昭衍新藥(06127)漲7.93% 機構指CXO景氣進入中報業績兑現期

中信建投：2026年國內CRO/CDMO行業的新簽訂單及業績會加速增長，帶動CXO產業鏈進入新一輪發展階段

中信建投：CXO板塊Beta穩中向好個股訂單加速兑現

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/WX/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"WX","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","market":"US","secType":"STK","nameCN":"Corgi All World 2x Daily ETF","latestPrice":24.3948,"timestamp":1789675200000,"preClose":23.8247,"halted":0,"volume":16,"hourTrading":{"tag":"盘后","latestPrice":23.8247,"preClose":24.3948,"latestTime":"16:10 EDT","volume":6,"amount":145.2286,"timestamp":1789675804542,"change":-0.5701,"changeRate":-0.02337,"amplitude":0},"delay":0,"changeRate":0.023928947688743197,"floatShares":15000,"shares":15000,"eps":0,"marketStatus":"已收盤","change":0.5701,"latestTime":"09-17 16:00:00 EDT","open":23.8247,"high":24.3948,"low":24.3948,"amount":406,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":2,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"盤前交易","tradingStatus":1,"beginTime":1789718400000},"marketStatusCode":5,"adr":0,"exchange":"CBOE","adjPreClose":23.8247,"nav":23.81,"aum":357150,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":23.8247,"preClose":24.3948,"latestTime":"16:10 EDT","volume":6,"amount":145.2286,"timestamp":1789675804542,"change":-0.5701,"changeRate":-0.02337,"amplitude":0},"volumeRatio":0.163265},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"WX\",,,,,undefined,":{"symbol":"WX","floatShares":15000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":0.163265,"shares":15000,"dividePrice":0,"high":24.3948,"amplitude":0,"preClose":23.8247,"low":24.3948,"week52Low":20.48,"pbRate":"--","week52High":25.58,"institutionHeld":0,"latestPrice":24.3948,"eps":0,"divideRate":0,"volume":16,"delay":0,"ttmEps":0,"open":23.8247,"prevYearClose":24.72,"prevWeekClose":24.6313,"prevMonthClose":24.9073,"prevQuarterClose":23.5672,"fiveDayClose":24.2097,"twentyDayClose":25.0033,"sixtyDayClose":23.76},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/WX\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"WX\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"WX\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"WX\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2657698357","title":"港股CXO近日股價集體走高，盈警之後的泰德醫藥(03880)將逆市下跌還是超跌反彈？","url":"https://stock-news.laohu8.com/highlight/detail?id=2657698357","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657698357?lang=zh_tw&edition=fundamental","pubTime":"2026-08-07 10:22","pubTimestamp":1786069332,"startTime":"0","endTime":"0","summary":"7月31日盘后，泰德医药发布了其26H1财年盈警公告。目前泰德医药尚未迎来连续数个交易日的低点逐步抬高以彻底终结下跌趋势，关键的量能均线也尚未出现明显转折。近日，港股医药概念股集体走高，CXO、创新药板块多点爆发，带动恒生医疗保健指数强势反弹。以8月4日行情为例，港股CXO板块出现一波个股集体走高，其中药明康德股价大涨11.17%，康龙化成和泰格医药均涨超5%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1477144.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03880","NIFE","CXO","BK4588","VXUS","KCAI","WX","BK4585","BK1141"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657657002","title":"【券商聚焦】中信建投：CXO 行業復甦明確，海內外醫藥投融資同步回暖","url":"https://stock-news.laohu8.com/highlight/detail?id=2657657002","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657657002?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 09:04","pubTimestamp":1785978243,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，国内CXO行业经历22-24年的调整阶段后，受益海外投融资率先回暖，24年国内头部CXO公司海外订单展现复苏态势，随着25年国内创新药资产实现大规模对外授权，带动国内投融资25H2持续复苏，行业内需同样企稳回升。26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国","market":"fut","thumbnail":"https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250106/ODRhMzI4MWM5YTc2MTY1NjgxNGQwMTEwODUwOTcyNzQ0Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987586","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["WX","09939","601066","BK1574","BK1515","KCE","BK0276","159938","CXO","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657572212","title":"中信建投：CXO板塊Beta穩中向好，AI製藥大有可為","url":"https://stock-news.laohu8.com/highlight/detail?id=2657572212","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657572212?lang=zh_tw&edition=fundamental","pubTime":"2026-08-06 07:41","pubTimestamp":1785973273,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["WX","CHAT","CXO","VTHR","AGIX","AIPO","QTOC","ARTY"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657591587","title":"CXO巨頭爆量上漲！開盤45分鐘成交120億元，超上日全天！規模最大醫療ETF（512170）創本輪反彈新高","url":"https://stock-news.laohu8.com/highlight/detail?id=2657591587","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657591587?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 10:35","pubTimestamp":1785897300,"startTime":"0","endTime":"0","summary":"CXO巨头药明康德重磅财报继续发酵！8月5日早盘，药明康德A股爆量上行，盘初一度续涨逾6%，截至10：15涨4.6%，成交超120亿元，超越上日全天，跻身A股成交额前五！全市场规模最大医疗ETF华宝同步上扬，场内价格创本轮反弹新高！数据显示，药明康德为医疗ETF华宝第一大重仓股，最新持仓占比达12.69%。高效参与CXO交易，关注两大“利器”：医疗ETF华宝：全市场规模最大医药医疗类ETF，聚焦医疗器械+医疗服务，兼顾AI医疗概念。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-05/doc-inimfshm5200987.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159828","512170","WX","CXO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657619592","title":"反轉信號已現，藥明只是導火索","url":"https://stock-news.laohu8.com/highlight/detail?id=2657619592","media":"虎嗅APP","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657619592?lang=zh_tw&edition=fundamental","pubTime":"2026-08-05 07:58","pubTimestamp":1785887880,"startTime":"0","endTime":"0","summary":"2026年2季度，共有793个机构投资者披露持有药明康德A股，合计持股量达10.93亿股，占总股本的36.64%。2026年6月末，药明康德有664.3亿元的在手订单，同比增长25.2%，超1季度23.6%的增幅。行业反转信号现，药明只是导火索此前市场对CXO行业最大的疑虑是“订单有改善，但利润没出来”，但2026年中报正在打破这个质疑。2026年6月8日，药明康德被新增列入。药明康德已于6月11日提起诉讼，目前尚未裁决。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://mp.weixin.qq.com/s?__biz=MTQzMjE1NjQwMQ==&mid=2656191578&idx=3&sn=832b803cb4237ffa6df707ef821c3501&chksm=671c8735cca01ad5e39d65b82e0f5f3051390a006108bde4292a28549d69473cd36634de313a&scene=0#rd","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"weixin_highlight","symbols":["WX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656589128","title":"創新藥產業鏈全線走強！CXO巨頭半年淨利首超百億元，績後飆漲逾10%！創新藥龍頭回暖，520880放量上探2.58%","url":"https://stock-news.laohu8.com/highlight/detail?id=2656589128","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656589128?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 11:07","pubTimestamp":1785812820,"startTime":"0","endTime":"0","summary":"8月4日早盘，创新药产业链全线走强，港股一马当先！港股通创新药龙头多股回暖，百济神州、石药集团、康方生物、中国生物制药等批量涨超1%，100%创新药研发标的——港股通创新药ETF华宝盘初放量上探2.58%！CXO巨头药明康德半年度业绩大增，绩后跳空高开，港股股价一度暴涨超14%！8月3日晚间，药明康德披露了上半年业绩，超出市场预期。这是公司净利润首次在上半年突破百亿元大关。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-04/doc-inimchzm4203295.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LNGR","520880","MEDX","WX","06978","159992","CXO","BK1161","IBBQ","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656158919","title":"港股異動 | CRO概念股漲幅居前 近期多家海外MNC與CXO披露中報盈喜並上調全年指引","url":"https://stock-news.laohu8.com/highlight/detail?id=2656158919","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656158919?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 11:05","pubTimestamp":1785812703,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，CRO概念股涨幅居前，截至发稿，药明康德涨11.05%，报180.9港元；金斯瑞生物科技涨10.18%，报17.96港元；凯莱英涨7.71%，报117.4港元；药明生物涨3.92%，报40.34港元。消息面上，药明康德公告称，上半年公司实现营业收入288.97亿元，同比增长38.93%；归母净利润110.8亿元，同比增长29.43%。值得注意的是，近期已有多家多家海外MNC与CXO披露中报盈喜并上调全年指引。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1475611.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU0516422440.USD","BK1610","LU0043850808.USD","LU1242518931.SGD","LU0456827905.SGD","02359","LU0359202008.SGD","LU0516423174.USD","LU0348767384.USD","LU0823426480.USD","LU1720050803.USD","LU1046422090.SGD","BK1589","01548","BK1191","LU0456846285.SGD","LU0856984785.SGD","LU0348766576.USD","LU1242518857.USD","HK0000306701.USD","LU0039217434.USD","CXO","HK0000306685.HKD","LU0708995583.HKD","LU0140636845.USD","LU0327786744.USD","LU1688375341.USD","SG9999002463.SGD","LU0516422952.EUR","BK1521","KCAI","LU0417516738.SGD","LU0979878070.USD","02269","BK4585","BK1141","VXUS","LU0348825331.USD","BK1576","LU0181495838.USD","LU3063872942.SGD","LU0417516902.SGD","KURE","06821","BK1583","LU0052750758.USD","LU0588546209.SGD","LU1794554557.SGD","WX","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656958656","title":"業績炸裂！全年收入劍指605億，藥明康德AH股價狂飆！高「CXO含量」港股通醫療ETF華寶（159137）暴升逾5%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2656958656","media":"新浪基金","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2656958656?lang=zh_tw&edition=fundamental","pubTime":"2026-08-04 09:47","pubTimestamp":1785808020,"startTime":"0","endTime":"0","summary":"药明康德业绩炸裂，CXO板块大受提振！8月4日早盘，药明康德AH股跳空高开，携手狂飙，A股涨停封板，港股一度暴涨超14%。港股通医疗ETF华宝近5成仓位布局CXO，场内价格一度暴涨超5%！全市场规模最大医疗ETF华宝CXO含量近30%，现涨超2%。8月3日晚，药明康德发布半年报，公司上半年实现营业收入288.97亿元，同比增长38.93%；归属于上市公司股东的净利润110.8亿元，同比增长29.43%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-08-04/doc-inimchzm4134226.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02359","LU0052750758.USD","LU1303224171.USD","BK1141","LU2328871848.SGD","LU0320764599.SGD","CXO","LU0348767384.USD","LU1934453819.USD","WX","BK1583","LU1046422090.SGD","LU0611395673.USD","LU2495084118.USD","LU1251922891.USD","IE00B5MMRT66.SGD","LU1979443071.USD","LU1808992512.USD","LU0700851271.USD","LU2488822045.USD","LU1719994722.HKD","603259","BK1576","LU2045819591.USD","LU0456842615.SGD","BK0216","LU1997245177.USD","LU1997245094.SGD","IE00BPRC5H50.USD","LU2242644610.SGD","FLHK","LU1770034418.SGD","159137","LU1969619763.USD","IE00B543WZ88.USD","LU0348766576.USD","512170","LU1997244956.HKD","LU2125910500.SGD","LU0708995583.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655933513","title":"再次突破半年線！全市場規模最大醫療ETF（512170）摸高1.54%，AI醫療、CXO攜手拉漲！港股通醫療同步走強","url":"https://stock-news.laohu8.com/highlight/detail?id=2655933513","media":"新浪基金","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655933513?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 10:52","pubTimestamp":1785466320,"startTime":"0","endTime":"0","summary":"7月31日，A股医疗板块低开高走，全市场规模最大医疗ETF华宝上探1.54%，连续第3日盘中突破半年线！成份股涨跌互现，AI医疗概念领涨，迪安诊断、九安医疗、奕瑞科技齐涨超7%。医疗器械回调，迈瑞医疗、联影医疗跌逾1%。港股通医疗ETF华宝：重仓创新药产业链，48%CXO+20%创新药，兼顾AI医疗、医疗器械等领域稀缺龙头，底层资产是港股，高弹性，T+0。","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/money/fund/etf/2026-07-31/doc-inikshrh9344635.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["WX","QTOC","AIPO","512170","FLHK","CXO","159891","VTHR","AGIX","ARTY","159828","CHAT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655724380","title":"【券商聚焦】中信建投：CXO個股訂單加速兑現，行業內需企穩回升","url":"https://stock-news.laohu8.com/highlight/detail?id=2655724380","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2655724380?lang=zh_tw&edition=fundamental","pubTime":"2026-07-31 09:12","pubTimestamp":1785460332,"startTime":"0","endTime":"0","summary":"26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，该机构认为26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。","market":"fut","thumbnail":"https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/M2QyMTYxN2UxNmI4NDk2OTg5NThlNDVhNTUzNjZhZTcxMjcxMzE0NDc4MDA=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1987181","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02196","09688","BK1500","KCE","LU0348767384.USD","WX","02367","LU2476274308.USD","01530","02228","IE00B3M56506.USD","LU0348735423.USD","LU0540923850.HKD","LU1794554557.SGD","LU1961090484.USD","LU2488822045.USD","SG9999004311.SGD","01099","KURE","LU1969619763.USD","BK1617","LU1251922891.USD","BK1585","LU0348827113.USD","LU2778985437.USD","CXO","LU0634319403.HKD","09926","BK1515","LU0348825331.USD","BK1161","LU2328871848.SGD","BK1141","IE00B5MMRT66.SGD","601066","LU0417516571.SGD","06821","LU0640798160.USD","01789","03933","06160","LU1303224171.USD","LU1770034418.SGD","LU2476274720.SGD","02268","BK1191","LU0348784397.USD","LU0348783233.USD","BK0276","BK1197"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2654095486","title":"醫藥外包概念全線揚升 昭衍新藥(06127)漲7.93% 機構指CXO景氣進入中報業績兑現期","url":"https://stock-news.laohu8.com/highlight/detail?id=2654095486","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2654095486?lang=zh_tw&edition=fundamental","pubTime":"2026-07-27 10:17","pubTimestamp":1785118673,"startTime":"0","endTime":"0","summary":"消息面上，开源证券新近研究指出，7月以来，康龙化成、昭衍新药、美迪西和药康生物先后发布2026年H1业绩预增公告，从早研到临床前研究，CXO景气周期已逐步进入利润表兑现期。根据医药魔方，2026H1全球创新药一级市场共发生505起融资事件，同比增长6.1%，融资金额达到267.5亿美元，同比增长58.5%。2026H1中国相关交易数量及金额涨势迅猛，总金额达997亿美元。从6月初至今，CXO板块在业绩和订单的支撑下，率先于创新药反弹。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/NmNiNTg2NTUyNjE5NjAwNw==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1986787","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","HK0000306685.HKD","KURE","LU0140636845.USD","LU0823426308.USD","06127","159938","LU0856984785.SGD","SG9999002562.SGD","LU0823426480.USD","LU0307460666.USD","03759","LU0359201612.USD","01548","603127","LU0516422440.USD","LU0327786744.USD","LU0348766576.USD","BK1583","BK1610","LU1242518857.USD","LU0039217434.USD","09939","LU2039709279.SGD","01873","BK1574","LU0588546209.SGD","LU0043850808.USD","LU0348767384.USD","03347","BK0216","LU2242644610.SGD","LU3063872942.SGD","06821","HK0000320264.USD","LU1242518931.SGD","LU2125910500.SGD","LU0516423174.USD","02269","LU1046422090.SGD","LU0348735423.USD","BK1161","BK1589","BK1141","LU0417516738.SGD","LU0516422952.EUR","WX","CXO","LU1880383366.USD","02359"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653772632","title":"中信建投：2026年國內CRO/CDMO行業的新簽訂單及業績會加速增長，帶動CXO產業鏈進入新一輪發展階段","url":"https://stock-news.laohu8.com/highlight/detail?id=2653772632","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653772632?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 08:20","pubTimestamp":1784852419,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4139","WX","CXO","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653774203","title":"中信建投：CXO板塊Beta穩中向好 個股訂單加速兑現","url":"https://stock-news.laohu8.com/highlight/detail?id=2653774203","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2653774203?lang=zh_tw&edition=fundamental","pubTime":"2026-07-24 07:45","pubTimestamp":1784850351,"startTime":"0","endTime":"0","summary":"26年至今国内创新药行业的长期结构性机会持续兑现，国内投融资持续改善，新药物形式赛道持续火热并进一步放量，26年国内CRO/CDMO行业的新签订单及业绩会加速增长，带动CXO产业链进入新一轮发展阶段。随着资金由融资端向CXO逐级传导，叠加板块估值仍处历史较低水平，行业业绩与估值有望持续修复。行业调整基本完成，Beta修复与个股Alpha进入兑现期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1471713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["CXO","WX","BK0276","601066"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":3,"pageCount":3,"totalSize":53,"code":"91000000","status":"200"}]}}